File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Decreased sensitivity to adenosine in platelets from patients with familial hypercholesterolaemia - A change reversed by cholestyramine treatment

TitleDecreased sensitivity to adenosine in platelets from patients with familial hypercholesterolaemia - A change reversed by cholestyramine treatment
Authors
KeywordsAdenosine receptors
cholestyramine
cyclic AMP
familial hypercholesterolaemia
platelet aggregation
Issue Date1993
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/ECI
Citation
European Journal Of Clinical Investigation, 1993, v. 23 n. 12, p. 803-811 How to Cite?
AbstractPlatelet-rich plasma was obtained from patients with untreated heterozygous familial hypercholesterolaemia (FH), from FH patients treated with cholestyramine and from control subjects. Responsiveness of platelets to the aggregation inhibitors adenosine, its analogue N-ethylcarboxamidoadenosine (NECA) and prostaglandin I2 was decreased in FH. Patients on cholestyramine therapy showed normal responsiveness to adenosine and NECA. There were only minor changes in the binding of [3H]NECA to high-affinity binding sites on platelet membranes from untreated FH or cholestyramine-treated FH patients. The initial rate of cyclic AMP formation in response to a high concentration of NECA was severely decreased in platelets from FH patients. By contrast, the rate of cyclic AMP formation in response to forskolin or a high concentration of prostaglandin I2 was unchanged. These data point to a defect in the coupling of the platelet A2 adenosine receptor to adenylyl cyclase in untreated FH patients.
Persistent Identifierhttp://hdl.handle.net/10722/162017
ISSN
2023 Impact Factor: 4.4
2023 SCImago Journal Rankings: 1.270
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorGasser, JAen_US
dc.contributor.authorCooper, MBen_US
dc.contributor.authorTan, KCBen_US
dc.contributor.authorSaggerson, EDen_US
dc.contributor.authorBetteridge, DJen_US
dc.date.accessioned2012-09-05T05:16:42Z-
dc.date.available2012-09-05T05:16:42Z-
dc.date.issued1993en_US
dc.identifier.citationEuropean Journal Of Clinical Investigation, 1993, v. 23 n. 12, p. 803-811en_US
dc.identifier.issn0014-2972en_US
dc.identifier.urihttp://hdl.handle.net/10722/162017-
dc.description.abstractPlatelet-rich plasma was obtained from patients with untreated heterozygous familial hypercholesterolaemia (FH), from FH patients treated with cholestyramine and from control subjects. Responsiveness of platelets to the aggregation inhibitors adenosine, its analogue N-ethylcarboxamidoadenosine (NECA) and prostaglandin I2 was decreased in FH. Patients on cholestyramine therapy showed normal responsiveness to adenosine and NECA. There were only minor changes in the binding of [3H]NECA to high-affinity binding sites on platelet membranes from untreated FH or cholestyramine-treated FH patients. The initial rate of cyclic AMP formation in response to a high concentration of NECA was severely decreased in platelets from FH patients. By contrast, the rate of cyclic AMP formation in response to forskolin or a high concentration of prostaglandin I2 was unchanged. These data point to a defect in the coupling of the platelet A2 adenosine receptor to adenylyl cyclase in untreated FH patients.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/ECIen_US
dc.relation.ispartofEuropean Journal of Clinical Investigationen_US
dc.subjectAdenosine receptors-
dc.subjectcholestyramine-
dc.subjectcyclic AMP-
dc.subjectfamilial hypercholesterolaemia-
dc.subjectplatelet aggregation-
dc.subject.meshAdenosine - Analogs & Derivatives - Metabolism - Pharmacologyen_US
dc.subject.meshAdenosine-5'-(N-Ethylcarboxamide)en_US
dc.subject.meshAdulten_US
dc.subject.meshCholestyramine Resin - Pharmacologyen_US
dc.subject.meshCyclic Amp - Blooden_US
dc.subject.meshEpoprostenol - Pharmacologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshForskolin - Pharmacologyen_US
dc.subject.meshHumansen_US
dc.subject.meshHyperlipoproteinemia Type Ii - Blooden_US
dc.subject.meshMaleen_US
dc.subject.meshPlatelet Aggregation Inhibitors - Pharmacologyen_US
dc.titleDecreased sensitivity to adenosine in platelets from patients with familial hypercholesterolaemia - A change reversed by cholestyramine treatmenten_US
dc.typeArticleen_US
dc.identifier.emailTan, KCB:kcbtan@hku.hken_US
dc.identifier.authorityTan, KCB=rp00402en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1365-2362.1993.tb00734.x-
dc.identifier.pmid8143757-
dc.identifier.scopuseid_2-s2.0-0027717092en_US
dc.identifier.volume23en_US
dc.identifier.issue12en_US
dc.identifier.spage803en_US
dc.identifier.epage811en_US
dc.identifier.isiWOS:A1993MM13200006-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridGasser, JA=35879184600en_US
dc.identifier.scopusauthoridCooper, MB=7404410514en_US
dc.identifier.scopusauthoridTan, KCB=8082703100en_US
dc.identifier.scopusauthoridSaggerson, ED=7006639728en_US
dc.identifier.scopusauthoridBetteridge, DJ=34973752700en_US
dc.identifier.issnl0014-2972-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats